Biotech · Public company · Miami Beach, FL, US

SAB Biotherapeutics, Inc.

Ticker SABS · SEC CIK 0001833214

Track this companyFree. Adds SAB Biotherapeutics, Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials62 recruiting or active

Pipeline programs5From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availableNo recent cash burn filed

Pipeline5

PRISE (Personalized Response and Immunologic Surveillance of Endogenous C-Peptide Preservation in New, Recent, and Established Onset Type 1 Diabetes Treated With Human Anti-Thymocyte Globulin [h-ATG]) StudyPHASE3 · NOT_YET_RECRUITING · started Sep 1, 2026ClinicalTrials.gov NCT07670650 · fetched Nov 12, 2026
SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 DiabetesPHASE2 · RECRUITING · started Nov 25, 2025ClinicalTrials.gov NCT07187531 · fetched Nov 12, 2026
A Study to Assess the Safety of SAB-176 to Prevent the Flu, Given IM in Healthy Adults Compared With PlaceboPHASE1 · UNKNOWN · started Apr 22, 2024ClinicalTrials.gov NCT06435936 · fetched Nov 12, 2026
Safety, Tolerability, and Pharmacokinetics of SAB-185 in Ambulatory Participants With COVID-19PHASE1 · UNKNOWN · started Aug 20, 2020ClinicalTrials.gov NCT04469179 · fetched Nov 12, 2026
Safety, Tolerability, and Pharmacokinetics of SAB-176 in Healthy ParticipantsPHASE1 · COMPLETED · started Jul 29, 2020ClinicalTrials.gov NCT04471038 · fetched Nov 12, 2026
Safety, Tolerability, and Pharmacokinetics of SAB-185 in Healthy ParticipantsPHASE1 · COMPLETED · started Jul 1, 2020ClinicalTrials.gov NCT04468958 · fetched Nov 12, 2026